Frontlight ResearchEarly access
Lung cancer trials in South Korea
152 of 170 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Phase 1/2 Study of IAM1363 in HER2 Cancers
- Where
- Seoul
- Age
- 18 years and over
- People
- 463 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 · EU 2024-519188-17-00 - Phase 3Taking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Bupyeong-gu, Busan, Daejeon, Deagu, Seoul, Yangsan
- Age
- 18 years and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - Phase 3Taking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Goyang-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Busan, Cheongju-si, Namdong-gu, Seoul, Yangsan
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 1Taking peopleA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- EpiBiologics
See details and how to joinNCT07462377 - Phase 2Not yet taking people in South KoreaA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
- Where
- Cheongju-si, Jinju, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07941609 - Phase 1Taking peopleA Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Where
- Haeundae, Seoul
- Age
- 18 years to 99 years
- People
- 600 worldwide
- Run by
- Erasca, Inc.
See details and how to joinNCT06983743 · EU 2026-525794-39-00 - Phase 1Taking peopleA Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Where
- Cheongju-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07277413 - Phase 2/3Taking peopleA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Daegu, Hwasun, Incheon, Seoul
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - Phase 3Taking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Daegu, Goyang-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Cheongju-si, Goyang-si, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 1Taking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Daejeon, Seongnam, Seoul
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Busan, Goyang-si Gyeonggi-do, Incheon, Seoul, Yangsan-si, Gyeongsangnam-do
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Cheongju-si, Goyang-si, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 1Taking peopleBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Chungju, Seongnam, Seoul
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - Phase 1/2Active, not recruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Chungcheongbuk-do, Jongno -Gu, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Bupyeong-gu, Daegu, Hwasun, Incheon, Junggu, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Busan, Deagu, Haeundae-gu, Hwasun-gun, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 2/3Not yet taking people in South KoreaStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Cheongju-si, Goyang-si, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Busan, Daejeon, Jeollanam-do, Seoul, Yangsan
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 2Taking peopleA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Where
- Cheongju-si, Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07221474 · EU 2025-520902-37-00 - Phase 3Taking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Cheongju-si, Daegu, Goyang-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - Phase 3Not yet taking people in South KoreaBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- Goyang-si, Gyeonggi-do, Jeongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - Phase 1/2Taking peoplePhase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC
- Where
- Gyeonggi-do, Incheon, Seoul
- Age
- 19 years and over
- People
- 104
- Run by
- Txinno Bioscience Inc.
See details and how to joinNCT07933055